Latest Pharmacy News

Elixinol Wellness lifted Q3 gross profit 27% and delivered a fourth consecutive quarter of positive underlying operating cash flow, despite statutory operating cash flow remaining negative and cash below A$1 million. The proposed all-scrip Vitable acquisition could add scale, but shareholder approval and a thin liquidity buffer remain important next tests.

Vitura Health has opened FY2027 with a sharp improvement in EBITDA and lower operating costs, while revenue growth continued across its digital health businesses. The figures are unaudited, and the company still needs to prove that the improvement can survive the wind-down of Bupa-related telehealth volumes.

Firebrick Pharma has raised approximately $732,000 from strategic investors, with its Philippines licensing partner investing $631,750 to lift its holding above 10%. The funding will support US retail production, a Singapore product launch and working capital.

Nutritional Growth Solutions has completed its acquisition of Sprout Organic, installing founder Selasi Berdie as CEO and reshaping the group around infant, toddler and children’s nutrition. The deal lifts shares on issue to 964 million, while management targets A$870,000 in annualised savings.

Compumedics Limited (ASX:CMP) returned to profit in FY26 as record revenue, stronger cash generation and a sharp rise in MEG and SaaS sales reshaped its earnings profile. The company enters FY27 with A$28.3 million of open orders, but lower gross margins and uneven US and European execution remain key tests.

Firebrick Pharma has approved a phased push into US retail pharmacies after Nasodine online sales grew by more than 200% in FY26. Up to six regional pharmacy groups representing about 700 stores have expressed strong interest in early orders, although no binding orders have been disclosed.

Biome Australia Limited (ASX:BIO) delivered its second consecutive profitable year in FY26, with revenue rising 30% to $23.9 million and operating cash flow turning positive. But the headline $3.6 million profit includes a $2.4 million deferred tax benefit, leaving FY27 execution as the real test of the company’s growth plan.

Emyria has reported a sharp increase in FY26 revenue while expanding its psychedelic-assisted therapy network to five operational or announced clinics and 18 beds. Its first Sydney clinic is now fitted out and scheduled to begin treating patients in September, but utilisation and funding remain the next tests.

Immuron Limited has inked an exclusive US distribution deal for PROIBS®, a European-certified medical device targeting abdominal discomfort, marking a key step in its digestive health portfolio growth.

Adheris Health has achieved cashflow break-even in Q4 FY26 following a strategic reset focused on its US operations, cutting costs by over 30% and repositioning for growth in FY27 with a stronger digital pipeline.

Nuchev has inked a consignment-based distribution deal to launch the Kuci women’s health probiotic range nationally through Chemist Warehouse, marking a strategic expansion into women’s health.

LTR Pharma is shifting gears from clinical trials to commercial rollout, securing US partnerships for ROXUS and reporting encouraging SPONTAN Phase II data that supports FDA approval ambitions.